Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.77 USD | -7.97% | +0.36% | -13.71% |
Financials (USD)
Sales 2024 * | 947K | Sales 2025 * | 4.13M | Capitalization | 578M |
---|---|---|---|---|---|
Net income 2024 * | -279M | Net income 2025 * | -304M | EV / Sales 2024 * | 232 x |
Net cash position 2024 * | 359M | Net cash position 2025 * | 104M | EV / Sales 2025 * | 115 x |
P/E ratio 2024 * |
-1.72
x | P/E ratio 2025 * |
-1.75
x | Employees | 233 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.96% |
Latest transcript on Allogene Therapeutics, Inc.
1 day | -7.97% | ||
1 week | +0.36% | ||
Current month | +0.36% | ||
1 month | -19.94% | ||
3 months | -42.17% | ||
6 months | -6.10% | ||
Current year | -13.71% |
Managers | Title | Age | Since |
---|---|---|---|
Joshua Kazam
FOU | Founder | 47 | 17-10-31 |
David Chang
FOU | Founder | 64 | 18-03-31 |
Geoffrey Parker
DFI | Director of Finance/CFO | 59 | 23-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Bonderman
BRD | Director/Board Member | 81 | 18-04-30 |
Joshua Kazam
FOU | Founder | 47 | 17-10-31 |
Arie Belldegrun
FOU | Founder | 74 | 17-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.54% | 2 M€ | -25.75% | ||
0.08% | 0 M€ | 0.00% | - | |
0.06% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 2.77 | -7.97% | 2,512,902 |
24-05-16 | 3.01 | +1.01% | 2,900,062 |
24-05-15 | 2.98 | +0.68% | 3,479,476 |
24-05-14 | 2.96 | +2.07% | 8,476,542 |
24-05-13 | 2.9 | +5.07% | 1,163,373 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.71% | 578M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ALLO Stock